Inflammation biomarkers and mortality prediction in patients with type 2 diabetes (ZODIAC-27)

Atherosclerosis

Volumn 250, Issue , 2016, Pages 46-51

  Landman, Gijs W D ^a,b   Kleefstra, Nanne ^a,c   Groenier, Klaas H ^c,d   Bakker, Stephan J L ^c   Groeneveld, Geert H ^e   Bilo, Henk J G ^c,d   van Hateren, Kornelis J J ^a  

^a LANGERHANS MEDICAL RESEARCH GROUP   (Netherlands)

^b GELRE HOSPITALS   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d ISALA HOSPITAL   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarker; Inflammation; Mortality; Prediction; Type 2 diabetes

Indexed keywords

ADRENOMEDULLIN; C REACTIVE PROTEIN; PROCALCITONIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; MORTALITY RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; AGED; BLOOD; BODY MASS; COMPLICATION; INFLAMMATION; METABOLISM; MIDDLE AGED; PRIMARY HEALTH CARE; PROPORTIONAL HAZARDS MODEL; SEX DIFFERENCE; STATISTICAL MODEL;

AGED; BIOMARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PRIMARY HEALTH CARE; PROPORTIONAL HAZARDS MODELS; SEX FACTORS;

EID: 84965176301     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.04.015     Document Type: Article

References (43)

1. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 2011, 11:98-107.
2. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454:428-435.
3. Devaraj S., Singh U., Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin. Chem. 2009, 55:229-238.
4. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 1997, 336:973-979.
5. Fernandez-Real J.M., Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr. Rev. 2003, 24:278-301.
6. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
7. Volanakis J.E. Human C-reactive protein: expression, structure, and function. Mol. Immunol. 2001, 38:189-197.
8. Bonnet J., McPherson R., Tedgui A., et al. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin. Ther. 2008, 30:2298-2313.
9. Kaptoge S., Di Angelantonio E., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140. Emerging Risk Factors, C.
10. Wang T.J. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 2011, 123:551-565.
11. Hingorani A.D., Shah T., Casas J.P., et al. C-reactive protein and coronary heart disease: predictive test or therapeutic target?. Clin. Chem. 2009, 55:239-255.
12. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 2004, 350:1387-1397.
13. Becker K.L., Nylen E.S., White J.C., et al. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J. Clin. Endocrinol. Metab. 2004, 89:1512-1525.
14. Jacobs J.W., Lund P.K., Potts J.T., et al. Procalcitonin is a glycoprotein. J. Biol. Chem. 1981, 256:2803-2807.
15. Linscheid P., Seboek D., Schaer D.J., et al. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit. Care Med. 2004, 32:1715-1721.
16. Lewis L.K., Smith M.W., Yandle T.G., et al. Adrenomedullin(1-52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage. Clin. Chem. 1998, 44:571-577.
17. Morgenthaler N.G., Struck J., Alonso C., et al. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin. Chem. 2005, 51:1823-1829.
18. Ataoglu H.E., Yilmaz F., Uzunhasan I., et al. Procalcitonin: a novel cardiac marker with prognostic value in acute coronary syndrome. J. Int. Med. Res. 2010, 38:52-61.
19. Bektas F., Soyuncu S., Gunduz I., et al. The value of procalcitonin, a novel inflammatory marker, in the diagnosis of myocardial infarction and evaluation of acute coronary syndrome patients. J. Emerg. Med. 2011, 41:524-530.
20. Courtais C., Kuster N., Dupuy A.M., et al. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. Am. J. Emerg. Med. 2013, 31:215-221.
21. Dhillon O.S., Khan S.Q., Narayan H.K., et al. Prognostic value of mid-regional pro-adrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study. J. Am. Coll. Cardiol. 2010, 56:125-133.
22. Elmas E., Lang S., Dempfle C.E., et al. Diagnostic performance of mid-regional pro-adrenomedullin as an analyte for the exclusion of left ventricular dysfunction. Int. J. Cardiol. 2008, 128:107-111.
23. Shah R.V., Truong Q.A., Gaggin H.K., et al. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur. Heart J. 2012, 33:2197-2205.
24. Landman G.W., van Dijk P.R., Drion I., et al. Midregional fragment of proadrenomedullin, new-onset albuminuria, and cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-30). Diabetes Care 2014, 37:839-845.
25. Cotoi O.S., Manjer J., Hedblad B., et al. Plasma procalcitonin is associated with all-cause and cancer mortality in apparently healthy men: a prospective population-based study. BMC Med. 2013, 11:180.
26. Schiopu A., Hedblad B., Engstrom G., et al. Plasma procalcitonin and the risk of cardiovascular events and death: a prospective population-based study. J. Intern Med. 2012, 272:484-491.
27. von Haehling S., Filippatos G.S., Papassotiriou J., et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur. J. Heart Fail. 2010, 12:484-491.
28. Wild P.S., Schnabel R.B., Lubos E., et al. Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study. Clin. Chem. 2012, 58:226-236.
29. Ubink-Veltmaat L.J., Bilo H.J., Groenier K.H., et al. Shared care with task delegation to nurses for type 2 diabetes: prospective observational study. Neth. J. Med. 2005, 63:103-110.
30. Lutgers H.L., Gerrits E.G., Graaff R., et al. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 2009, 52:789-797.
31. Eda S., Kaufmann J., Roos W., et al. Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range. J. Clin. Lab. Anal 1998, 12:137-144.
32. Price C.P., Trull A.K., Berry D., et al. Development and validation of a particle-enhanced turbidimetric immunoassay for C-reactive protein. J. Immunol. Meth 1987, 99:205-211.
33. Morgenthaler N.G., Struck J., Fischer-Schulz C., et al. Sensitive immunoluminometric assay for the detection of procalcitonin. Clin. Chem 2002, 48:788-790.
34. Schemper M., Henderson R. Predictive accuracy and explained variation in Cox regression. Biometrics 2000, 56:249-255.
35. May S., Hosmer D.W. A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal 1998, 4:109-120.
36. Matsushita K., Mahmoodi B.K., Woodward M., et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA: J. Am. Med. Assoc 2012, 307:1941-1951.
37. Fox C.S., Matsushita K., Woodward M., et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012, 380:1662-1673.
38. De Berardis G., Sacco M., Strippoli G.F., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009, 339:b4531.
39. Hira R.S., Kennedy K., Nambi V., et al. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the national cardiovascular disease registry's practice innovation and clinical excellence registry. J. Am. Coll. Cardiol 2015, 65:111-121.
40. Hilden J. Commentary: On NRI, IDI, and "good-looking" statistics with nothing underneath. Epidemiology 2014, 25:265-267.
41. Hilden J., Gerds T.A. A note on the evaluation of novel biomarkers: do not rely on integrated discrimination improvement and net reclassification index. Stat. Med 2014, 33:3405-3414.
42. Pencina M.J., Neely B., Steyerberg E.W. RE: net risk reclassification P Values: valid or misleading?. J. Natl. Cancer Inst 2015, 107:355.
43. Pepe M., Fan J., Feng Z., et al. The Net Reclassification Index (NRI): A misleading measure of prediction improvement even with independent test data sets, Stat. Biosci 2014, 1-14.